, Genetic changes in squamous cell lung cancer: a review, J. Thorac. Oncol, vol.7, pp.924-933, 2012.
, Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype, EMBO Mol. Med, vol.6, pp.539-550, 2014.
, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J. Clin. Oncol, vol.22, pp.2184-2191, 2004.
, Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer, Oncologist, vol.15, pp.436-446, 2010.
, Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor, Proc. Natl Acad. Sci. USA, vol.90, pp.10705-10709, 1993.
, A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use, J. Cell. Mol. Med, vol.14, pp.528-552, 2010.
, Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR, Biochem. Biophys. Res. Commun, vol.226, pp.324-328, 1996.
, Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate, Proc. Natl Acad. Sci. USA, vol.95, pp.8795-8800, 1998.
, Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization, PLoS One, vol.7, p.33576, 2012.
, Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer, Br. J. Cancer, vol.92, pp.553-561, 2005.
, Markers of response for the antiangiogenic agent bevacizumab, J. Clin. Oncol, vol.31, pp.1219-1230, 2011.
, Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients, Proc. Natl Acad. Sci. USA, vol.112, pp.14325-14330, 2015.
, Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer, Proc. Natl Acad. Sci. USA, vol.112, pp.1547-1552, 2015.
, Statistical analyses were performed using a non parametric Mann-Whitney test. c Mean levels ± SD of ?1 integrin immunohistochemical scores according to the sVEGFR1-i13 status in ADC (white boxes) and SQLC (hatched boxes), where + and -represent tumours with high or low levels of sVEGFR1-i13 compared to normal lung tissues respectively. Statistical analyses were performed using a non parametric Mann-Whitney test. d Mean levels ± SD of ?1 integrin+sVEGFR1-i13 immunohistochemical scores according to P-VEGFR1(Tyr1213) status in ADC (white boxes) and SQLC (hatched boxes), where + and -represent tumours with high or low levels of P-VEGFR1(Tyr1213) compared to normal lung tissues respectively. Statistical analyses were performed using a non parametric Mann-Whitney test. e Mean levels ± SD of MAS5-normalised sVEGFR1-i13 mRNA in SQLC patients taken from the GSE4573 database expressing either low (<25th percentile), medium (25-75th percentile) or high (>75th percentile) levels of ?1 integrin (ITGB1) mRNA. Statistical analyses were performed using Kruskal-Wallis test. f Kaplan-Meier univariate survival analysis of SQLC patients with pTNM I/II stage according to high (>75th percentile; 4th quartile) or low/medium (<75th percentile; 1st-3rd quartiles) sVEGFR1-i13 and ?1 integrin (ITGB1) mRNA levels. h Left panels: anti-angiogenic therapies increase the level of sVEGFR1-i13 in squamous lung tumour cells. However, whether cells respond or do not respond to anti-angiogenic therapies depends on the level of ?1 integrin. In cells with high levels of ?1 integrin (MGH7-like phenotype), the increase of sVEGFR1-i13 protein level upon anti-angiogenic treatment contributes to the activation of a ?1 integrin-dependent VEGFR1/ VEGFR2 autocrine loop. This loop promotes the tumour cell proliferation and survival, thereby escape from the treatment, sVEGFR1-i13/?1 integrin cross-talk is involved in SQLC tumour progression. a Representative sVEGFR1-i13 immunostainings from paraffin-embedded sections of normal lung tissues (upper panel: alveolus; lower panel: bronchus) as well as of two well-differentiated squamous cell lung carcinomas. Scores are indicated for each case. b Mean levels ± SD of sVEGFR1-i13 immunohistochemical scores according to the P-VEGFR1(Tyr1213) status in squamous cell lung carcinoma, where + and -represent tumours with high or low levels of P-VEGFR1 (Tyr1213) compared to normal lung tissues respectively
, Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin, J. Cell. Sci, vol.116, pp.3479-3489, 2003.
, Endothelial cell adhesion to soluble vascular endothelial growth factor receptor-1 triggers a cell dynamic and angiogenic phenotype, FASEB J, vol.28, pp.692-704, 2014.
, Soluble VEGF receptor 1 (sFLT1) induces non-apoptotic death in ovarian and colorectal cancer cells, Sci. Rep, vol.6, p.24853, 2016.
, E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35, Cell Death Differ, vol.15, pp.1815-1823, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00360967
, Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression, Br. J. Dermatol, vol.164, pp.1061-1070, 2011.
, International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma, J. Thorac. Oncol, vol.6, pp.244-285, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00561753
, Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma, PLoS One, vol.7, p.46539, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02337424
, E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short), Cell Death Differ, vol.13, pp.260-272, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00172959
, Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation, Mol. Cell, vol.43, pp.927-939, 2011.
, A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through alpha5beta1 integrin, Blood, vol.111, pp.3479-3488, 2008.
, Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung, Cancer Res, vol.66, pp.7466-7472, 2006.
, Soluble VEGFR-1: a new biomarker of sorafenibrelated hypertension (i.e., sorafenib-related is the compound adjective?), J. Clin. Pharmacol, vol.55, pp.478-479, 2015.
, Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer, PLoS One, vol.7, p.38231, 2012.
, Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer, Oncologist, vol.15, pp.577-583, 2010.
, Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study, J. Clin. Oncol, vol.27, pp.3020-3026, 2009.
, A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer, Clin. Cancer Res, vol.19, pp.6614-6623, 2013.
, Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis, Vasc. Cell, vol.3, p.15, 2011.
, VEGF-A induces its negative regulator, soluble form of VEGFR-1, by modulating its alternative splicing, FEBS Lett, vol.587, pp.2179-2185, 2013.
, A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia, J. Clin. Endocrinol. Metab, vol.94, pp.2524-2530, 2009.
, Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1, Proc. Natl Acad. Sci. USA, vol.108, pp.3276-3281, 2011.
, Jumonji domain containing protein 6 is decreased in human preeclamptic placentas and regulates sFLT-1 splice variant production, Biol. Reprod, vol.94, p.59, 2016.
, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science, vol.307, pp.58-62, 2005.
, Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial, Lancet, vol.384, pp.665-673, 2014.
, beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma, Cancer Res, vol.73, pp.3145-3154, 2013.
, beta1 integrin: critical path to antiangiogenic therapy resistance and beyond, Cancer Res, vol.74, pp.3-7, 2014.